

I nuovi concentrati di FVIII e di FIX: evidenze Elena Santagostino

A. Bianchi Bonomi Hemophilia & Thrombosis Center Ca' Granda Foundation, Maggiore Hospital Policlinico, Milano, Italy

Napoli, 23 marzo 2016

Issues with current treatment

- Prophylaxis should be started at very young ages
- Repeated intravenous injections can be problematic even in some adults
- Compliance and adherence to treatment (adolescents)
- No universal regimen = treatment individualization
- Inhibitor development








Long-acting products

Expected changes in prophylaxis patterns


	Current products (# yearly i.v. injections)	Long-acting products (# yearly i.v. injections)	
Hemophilia A	150-180	80-100	
Hemophilia B	100-120	30-40	

How will these longer acting concentrates impact on prophylaxis? Fewer infusions Higher troughs



The importance of higher troughs

- In the past trough levels between 1 and 3% were considered "enough"¹
- To protect from joint bleeds higher troughs are needed²
- The time spent below 1% resulted proportional to the incidence of break-through bleeds³




¹ Ahlberg A. Acta Orthop Scand 1965; 77 (Suppl): 3-132
²Den Uijl IE et al. Haemophilia 2011; 17: 849-53

Immunogenicity

Will they result in:

- More (>25-30%) won't be accepted
- SAME will be tolerated
- Less (<25%) hopefully</p>

So far so good in PTPs Awaiting for PUPs studies



Long-acting FVIII and FIX products


Molecule name	Structure	Availability	Brand/Company
rFIXFc	rFIX Fc fusion	 Marketed in USA/Canada PUPs trial ongoing 	Alprolix [®] /Biogen Idec
Nonacog beta pegol (N9-GP)	GlycoPEGylated FIX	- Extension study	NA/NovoNordisk
CSL-654 (rIX-FP)	rFIX albumin fusion	Extension studyPUPs trial ongoing	NA/CSL Behring
rFVIIIFc	rBDD-FVIII Fc fusion	 Marketed in USA/Canada PUPs trial ongoing 	Eloctate [®] /Biogen Idec
BAY 94-9027	PEGylated BDD-FVIII (60 KDa)	- Extension study	NA/Bayer Healthcare
N8-GP	GlycoPEGylated BDT- FVIII (40 KDa)	 Extension study PUPs trial ongoing 	NA/NovoNordisk
BAX-855	PEGylated FVIII (20 KDa)	- Extension study	NA/Baxter

BDD: B-Domain deleted; BDT: B-Domain truncated; NA: not applicable

Different technologies, different outcomes?

- Fusion technologies with physiological proteins as Fc fragment or albumin seems safer
- Fusion of FVIII to albumin failed to preserve effective coagulation activity

- Concerns about long-term exposure to PEG moiety
 - antibody production
 - accumulation???
 - long-term toxicity?
 - 20, 40, 60 kDa




Manufacturing process of rFIXFc

- Human embryonic kidney (HEK) 293H cells
- A single molecule of rFIX covalently fused to the Fc domain of human IgG1
- Transfected HEK 293H cells are grown in serum-free medium
- Specific analytical tests were used to assess identity, purity, activity and safety

Process step no.	Step description
Step 0	Thaw of one working cell bank vial
Step 1	Inoculum expansion (culture expansion in shake flasks) \downarrow
Step 2	Seed train bioreactors (culture expansion in bioreactors)
Step 3	Production bioreactor
Step 4	Harvest by centrifugation
Step 5	Clarification (depth filtration)
Step 6	Capture chromatography (MabSelect SuRe™)
Step 7	Product neutralization
Step 8	↓ Anion exchange chromatography
Step 9	Pseudo affinity chromatography
Step 10	↓ Virus reduction filtration (Planova 15N)
Step 11	Ultrafiltration∕diafiltration
Step 12	rFIXFc product
	formulation, filtration, bottling,
	and storage


McCue et al Haemophilia 2014; 20: e327-35

B-LONG: Phase 3 Study of rFIXFc in PTPs




- The median weekly dose was 45 IU/kg in group 1
- The median dosing interval was 12.5 days in group 2

B-LONG: Phase 3 Study of rFIXFc in PTPs




Paradigm 2: Phase 3 study of N9-GP




Bleeding episodes treated with single dose of 40 U/kg regardless of trial arm

Paradigm 2: Phase 3 study of N9-GP




rFIX Albumin Fusion Protein



- rIX-FP is a recombinant protein purified from CHO cells
- rIX-FP is generated by the genetic fusion of human recombinant albumin to the c-terminus of rFIX
- Cleavable linker between rFIX and albumin derived from rFIX activation region

rIX-FP yielding a longer duration of action could address the existing unmet medical needs by requiring less frequent dosing


Prolong9-FP: Phase I and I/II PK study



Santagostino E et al Blood 2012;1 20: 2405-11

Martinowitz U et al Thromb Res 2013; 131 (Suppl 2): S11-14

Prolong9-FP: Phase 3 study of rIX-FP



On-Demand vs. Prophylaxis with rIX-FP

	Within-subject comparison (n=19) rIX-FP		AsBR	
	On-demand period ~6 months	Prophylaxis period ~12 months	reduction	
AsBR, median (IQR)	15.43 (7.98–17.96)	0.0 (0.00–0.96)	100% (p<0.0001)	
Target joint(s), n (%)	10 (53)	0		
Estimated AsBR (95% CI) [†]	13.62 (11.00–16.87)	0.55 (0.23–1.32)		
Estimated total ABR (95% CI) [†]	18.22 (15.38-21.58)	1.81 (0.97–3.37)		
Median dose (IU/kg)		40 IU/kg		


7-, 10- and 14-Day Prophylaxis Regimens

•				
40 7-day Prophylaxis n=37 ~6 Months	10-day Prop	hylaxis n=21 phylaxis n=7 phylaxis n=9	Extension stud	
	>24 months			
	7-Day Regimen (n=40)	10-Day Regimen (n=7)	14-Day Regimen (n=21)	
AsBR				
Median (IQR)	0 (0, 0)	0 (0, 0)	0 (0, 1.0)	
Estimated mean AsBR (95% CI) [†]	0.65 (0.37–1.13)	0.56 (0.27–1.17)	0.83 (0.38–1.77)	
Total ABR				
Median (IQR)	0 (0, 1.87)	0 (0, 1.78)	1.08 (0, 2.7)	
Estimated mean ABR (95% CI) [†]	1.58 (1.02–2.44)	1.69 (0.87–3.28)	1.61 (0.93–2.80)	

Manufacturing process of rFVIIIFc

- Human embryonic kidney (HEK) 293H cells
- A single molecule of rFVIII covalently fused to the Fc domain of human IgG1
- Transfected HEK 293H cells are grown in serum-free medium
- · Specific analytical tests were used to assess identity, purity, activity and safety


Sample	α-Gal	α-Gal		NGNA	
	Average % mol/mol (n = 3)	Standard deviation (n = 3; %)	Average % mol/mol (inter-day; n = 9)ª	RSD ^b (inter-day; n = 9; %) ^a	
rFVIIIFc	<lod<sup>c</lod<sup>	NA	<lod<sup>d</lod<sup>	NA	
Xyntha	10.2	1.6	20.31 (0.73)	3.6	
Advate	3.3	0.6	1.33 (0.14)	10.8	
Kogenate	1.3°	0.8	5.99 (0.32)	5.3	
Positive control	41.7	0.4	-	-	
on-processed A	1 A2	5 ⁸ 3	A3 C1	C2 FC FC	
Processed A	1 A2	 	A3 C1	C2 FC	
	Glycosyla	ited asparagine	Sulfated tyrosine Free cysteine		




McCue et al Biologicals 2015; 43: 213-9

Levels of A) galactose-α-1,3-galactose (α-Gal) and B) N-glycolylneuraminic acid (NGNA) in rFVIIIFc and three commercially available rFVIII products.

A-LONG: Phase 3 Study of rFVIIIFc in PTPs




ASPIRE: Extension Study with rFVIIIFc in PTPs




No inhibitor development


Nolan B et al Haemophilia 2015; epub ahead of print

Post-hoc analysis on bleeding rates




Pathfinder 2: Phase 3 Study of N8-GP






Company announcement 19 march 2014

PROTECT-VIII: Phase 2/3 Study of BAY 94-9027 in PTPs



ClinicalTrials.gov identifier: NCT01580293

PROLONG-ATE: Phase 2/3 Study of BAX 855



Konkle B et al Blood 2015; 126: 1078-85

Longer-acting products: a new era for hemophilia prophylaxis? Challenges and Perspectives

- All novel investigative therapies are promising, however still associated with potential risks and real benefits are to be proven
- Treatment individualization is the best strategy
- Open issues:
 - long-term safety
 - laboratory monitoring
 - availability
 - costs